Compounds > fingolimod hydrochloride
Page last updated: 2024-09-02

fingolimod hydrochloride and piperidines

fingolimod hydrochloride has been researched along with piperidines in 4 studies

Compound Research Comparison

Studies
(fingolimod hydrochloride)		Trials
(fingolimod hydrochloride)		Recent Studies (post-2010)
(fingolimod hydrochloride)		Studies
(piperidines)		Trials
(piperidines)		Recent Studies (post-2010) (piperidines)
2,7711572,06240,2355,22114,545

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cassidy, MP; He, H; Milstien, S; Paugh, SW; Selley, DE; Sim-Selley, LJ; Spiegel, S1
Furberg, CD; Moore, TJ1
Baek, DJ; Bittman, R; MacRitchie, N; Pyne, NJ; Pyne, S1
Dolgin, E1

Other Studies

4 other study(ies) available for fingolimod hydrochloride and piperidines

ArticleYear
Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
    Molecular pharmacology, 2006, Volume: 70, Issue:1

    Topics: Animals; Benzoxazines; Binding, Competitive; Cell Line; CHO Cells; Cricetinae; Cricetulus; Cyclohexanes; Cyclohexanols; Endocytosis; Enzyme Activation; Fingolimod Hydrochloride; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Immunosuppressive Agents; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; Naphthalenes; Phenols; Piperidines; Propylene Glycols; Proto-Oncogene Proteins c-akt; Pyrazoles; Radioligand Assay; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Sphingosine

2006
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
    JAMA, 2012, Sep-05, Volume: 308, Issue:9

    Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Dabigatran; Drug Approval; Efficiency, Organizational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Patient Safety; Piperidines; Propylene Glycols; Quinazolines; Risk; Sphingosine; Stroke; Thyroid Neoplasms; Time Factors; United States; United States Food and Drug Administration

2012
Synthesis of selective inhibitors of sphingosine kinase 1.
    Chemical communications (Cambridge, England), 2013, Mar-14, Volume: 49, Issue:21

    Topics: Cell Line; Enzyme Inhibitors; Fingolimod Hydrochloride; HEK293 Cells; Humans; Phosphotransferases (Alcohol Group Acceptor); Piperidines; Propylene Glycols; Proteasome Endopeptidase Complex; Sphingosine

2013
Therapies: Progressive steps.
    Nature, 2016, 11-30, Volume: 540, Issue:7631

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, CD20; Azetidines; B-Lymphocytes; Benzamides; Benzyl Compounds; Blood-Brain Barrier; Clinical Trials as Topic; Disease Progression; Dogs; Drug Approval; Fingolimod Hydrochloride; Hope; Humans; Male; Mice; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Piperidines; Precision Medicine; Pyridines; Rituximab; Thiazoles; Ubiquinone; United States; United States Food and Drug Administration

2016